# 🔥 Hypernatremia

### 🚨 MOST COMMON CAUSE: Lack of Free Water Access

**Patients who CANNOT move or communicate their thirst**

#### 🧓 Elderly

- Dementia
- Stroke
- Nursing home residents
- Impaired thirst mechanism

#### 👶 Infants

- Cannot communicate thirst
- Concentrated formula
- Fever/illness
- Gastroenteritis

#### 🏥 Hospitalized

- Sedated/intubated
- Post-operative
- NPO restrictions
- Altered mental status

#### 🧠 Neurologic

- Spinal cord injury
- Cerebral palsy
- Psychiatric illness
- Developmental delay

⚠️ ALWAYS assess patient's ability to access and communicate need for water ⚠️

### 🎯 Key Concept: Free Water Deficit

**Water Deficit = TBW × \[(Current Na / 140) - 1\]**

Where TBW = Total Body Water (60% of body weight in kg for men, 50% for women, 45% for elderly)

## 🔍 Systematic Diagnostic Approach

### 📊 Initial Assessment

- **Volume Status:** Physical exam, vitals, I/O
- **Mental Status:** Confusion, seizures, coma
- **Access to Water:** Can patient drink? Communicate thirst?
- **Onset:** Acute (within 48 hours) versus chronic (longer than 48 hours) or unknown
- **Medications:** Diuretics, lithium, osmotic agents

### 🧪 Essential Laboratory Studies

- **Urine Osmolality:** KEY diagnostic test
- **Urine Volume:** Normal vs polyuria (\>3L/day)
- **Urine Sodium:** Assess volume status
- **Serum Osmolality:** Calculate osmolal gap
- **Glucose, BUN:** Rule out osmotic diuresis

### ⚠️ Clinical Manifestations

- **Mild (145-149):** Thirst, weakness, fatigue
- **Moderate (150-159):** Confusion, muscle cramps
- **Severe (≥160):** Seizures, coma, death
- **Rate Dependent:** Rapid onset more dangerous
- **Age Factor:** Children and elderly at higher risk

## 🔬 Diabetes Insipidus: Comprehensive Diagnostic Workup

### 🎯 DI Diagnosis: Urine Studies & Water Deprivation Test

#### 🧪 Initial Urine Studies

- **Urine Osmolality \<200 mOsm/kg:** Suggests DI
- **Urine Volume \>3L/day:** Polyuria threshold
- **Urine Specific Gravity \<1.005:** Dilute urine
- **24-hour urine volume:** Quantify losses

#### ⚡ DI Screening

- **If Uosm \>300:** DI unlikely
- **If Uosm \<200 + polyuria:** Proceed with water deprivation
- **Plasma osmolality \>295:** Supports DI diagnosis
- **Simultaneous measurements:** Critical for interpretation

### 💧 Water Deprivation Test Protocol

#### ⚠️ CONTRAINDICATIONS

- Severe hypernatremia (Na+ \>150 mEq/L)
- Volume depletion or hemodynamic instability
- Inability to monitor patient closely
- Psychiatric conditions affecting compliance

1 **BASELINE (Time 0):** Measure weight, vital signs, serum Na+, osmolality, urine osmolality\
• Patient should be normally hydrated • Start early morning • Obtain informed consent 2 **WATER RESTRICTION:** No fluids allowed for 8-12 hours (or until 3-5% weight loss)\
• Monitor hourly: weight, vitals, mental status • Collect urine hourly for volume and osmolality 3 **ENDPOINT CRITERIA:** Stop test when ANY of the following occur:\
• 3-5% weight loss • Urine osmolality plateaus (3 consecutive measurements within 30 mOsm/kg) • Serum Na+ \>145 mEq/L • Patient distress 4 **DESMOPRESSIN CHALLENGE:** Give DDAVP 2-4 mcg SC or 10-20 mcg intranasal\
• Measure urine osmolality at 1, 2, and 4 hours post-DDAVP • Continue monitoring vital signs

#### 📊 INTERPRETATION CRITERIA

##### Normal Response

Urine Osm \>600 mOsm/kg after dehydration. No significant change with DDAVP.

##### Central DI

Urine Osm \<300 mOsm/kg. \>50% increase after DDAVP (often \>100%).

##### Nephrogenic DI

Urine Osm \<300 mOsm/kg. \<10% increase after DDAVP. No response to ADH.

##### Partial Central DI

Urine Osm 300-600 mOsm/kg. 15-50% increase after DDAVP.

## 🧬 Etiology: Central vs Nephrogenic Diabetes Insipidus

### 🧠 Central Diabetes Insipidus (ADH Deficiency)

**Mechanism:** Inadequate ADH secretion from posterior pituitary

#### 🏥 Acquired Causes

- **Neurosurgery:** Transphenoidal surgery (most common)
- **Head Trauma:** Basilar skull fracture
- **Tumors:** Craniopharyngioma, pituitary adenoma
- **Infiltrative:** Sarcoidosis, histiocytosis
- **Infections:** Meningitis, encephalitis
- **Vascular:** Sheehan syndrome, aneurysm

#### 🧬 Congenital Causes

- **Familial:** AVP gene mutations (rare)
- **Autosomal Dominant:** Usually presents in childhood
- **DIDMOAD Syndrome:** DI + diabetes mellitus + optic atrophy + deafness
- **Septo-optic Dysplasia:** Pituitary hypoplasia

#### 💊 Treatment

- **DDAVP (Desmopressin):** First-line therapy
- **Intranasal:** 10-40 mcg daily (divided doses)
- **Oral:** 0.1-1.2 mg daily (divided doses)
- **Parenteral:** 1-4 mcg SC/IV daily
- **Monitoring:** Urine output, serum sodium

### 🏗️ Nephrogenic Diabetes Insipidus (ADH Resistance)

**Mechanism:** Kidney unresponsive to ADH despite normal/elevated levels

#### 💊 Drug-Induced (Most Common)

- **LITHIUM:** \#1 cause (20-40% of patients)
- **Mechanism:** Blocks ENaC channels, downregulates AQP2
- **Reversibility:** May be irreversible after years of use
- **Demeclocycline:** Tetracycline antibiotic
- **Amphotericin B:** Antifungal medication
- **Osmotic Diuretics:** Mannitol, radiocontrast

#### ⚡ Electrolyte Disorders

- **Hypokalemia:** K+ \<3.0 mEq/L impairs concentrating
- **Hypercalcemia:** Ca2+ \>11 mg/dL
- **Mechanism:** Interferes with ADH action on collecting duct
- **Reversible:** Correcting electrolyte normalizes function

#### 🏥 Medical Conditions

- **Chronic Kidney Disease:** Loss of medullary gradient
- **Sickle Cell Disease:** Medullary infarction
- **Polycystic Kidney Disease:** Structural damage
- **Sjögren's Syndrome:** Autoimmune tubulointerstitial disease
- **Hypoxic Injury:** Post-acute tubular necrosis

#### 🧬 Congenital Forms

- **X-linked:** AVPR2 gene (ADH receptor)
- **Autosomal Recessive:** AQP2 gene (water channel)
- **Presentation:** Early infancy, failure to thrive
- **Prognosis:** Lifelong condition

#### 💊 Treatment Approach

- **Thiazide Diuretics:** HCTZ 25-50 mg daily
- **Amiloride:** 5-10 mg daily (especially for lithium)
- **Low Sodium Diet:** \<2g/day to enhance thiazide effect
- **NSAIDs:** Indomethacin 50-150 mg daily (short-term)
- **Free Water Access:** Ensure adequate intake

#### ⚠️ Lithium Management

- **Check Lithium Level:** Target 0.6-0.8 mEq/L
- **Amiloride First-Line:** Blocks lithium uptake
- **Consider Discontinuation:** If severe/progressive
- **Alternative Mood Stabilizers:** Valproate, carbamazepine
- **Regular Monitoring:** Urine concentrating ability

## 💧 Hypercalcemia-Induced Nephrogenic Diabetes Insipidus: Detailed Mechanism

### 🎯 CRITICAL CONNECTION: How Hypercalcemia Causes Nephrogenic DI

#### 🔬 Cellular Mechanisms

1.  **Aquaporin-2 (AQP2) Downregulation:**
    - Hypercalcemia directly reduces AQP2 expression
    - Decreased water channel insertion into apical membrane
    - Impaired water reabsorption in collecting duct
2.  **ADH Receptor (V2R) Dysfunction:**
    - Calcium interferes with V2 receptor signaling
    - Disrupted cAMP-protein kinase A pathway
    - Reduced responsiveness to circulating ADH
3.  **Medullary Concentrating Defect:**
    - Calcium deposition (nephrocalcinosis)
    - Chronic tubulointerstitial nephritis
    - Loss of medullary concentration gradient

#### 📊 Clinical Threshold & Presentation

- **Critical Threshold:** Ca++ \>11.5 mg/dL consistently
- **Dose-Response:** Higher calcium = more severe NDI
- **Polyuria:** \>3L/day urine output (can be \>10L/day)
- **Polydipsia:** Compensatory increased thirst
- **Urine Osmolality:** \<300 mOsm/kg (inappropriately dilute)
- **Urine Specific Gravity:** \<1.010
- **Dehydration Risk:** High if water access limited
- **Hypernatremia:** Common complication (Na+ often \>150)

#### ⚠️ CLINICAL VIGNETTE: Typical Presentation

**Scenario:** 65-year-old with known malignancy presents with confusion, polyuria (6L/day), and polydipsia. Labs: Ca++ 13.2 mg/dL, Na+ 158 mEq/L, urine osmolality 180 mOsm/kg.\
**Diagnosis:** Malignancy-associated hypercalcemia causing nephrogenic DI leading to hypernatremia.

### 💊 Treatment Strategy for Hypercalcemic NDI

#### 🎯 Primary Goal: Normalize Calcium

- **Aggressive Hydration:** Normal saline 200-300 mL/hr
- **Bisphosphonates:** Zoledronic acid 4mg IV (definitive)
- **Calcitonin:** 4 IU/kg IM/SC q12h (rapid onset)
- **Furosemide:** After adequate hydration
- **Target Ca++:** \<11.5 mg/dL to reverse NDI

#### 💧 NDI-Specific Measures

- **Free Water Access:** Ensure adequate oral intake
- **Hypotonic Fluids:** D5W or 0.45% saline
- **Thiazide Diuretics:** HCTZ 25mg daily (paradoxical effect)
- **Amiloride:** 5-10mg daily (if concurrent lithium)
- **Monitor Closely:** Na+, Ca++, urine output, mental status

#### ⏰ Timeline & Expectations

- **Calcitonin Effect:** 2-6 hours (temporary)
- **Bisphosphonate Effect:** 24-72 hours (sustained)
- **NDI Reversal:** Usually within 2-7 days of Ca++ normalization
- **Complete Recovery:** May take 2-4 weeks
- **Monitoring Frequency:** Ca++ and Na+ q6h initially

#### 🔄 Reversibility and Prognosis

##### ✅ Good Prognosis (Reversible)

- Acute hypercalcemia (\<1 month duration)
- Functional NDI (no structural damage)
- Young patients with good kidney function
- Treatable underlying malignancy

##### ⚠️ Guarded Prognosis (May be Permanent)

- Chronic hypercalcemia (\>6 months)
- Severe nephrocalcinosis on imaging
- Concurrent chronic kidney disease
- Advanced age or multiple comorbidities

#### 📋 MONITORING PROTOCOL FOR HYPERCALCEMIC NDI

##### Every 4-6 Hours

- Serum sodium
- Serum calcium
- Neurologic assessment
- Vital signs

##### Every 8-12 Hours

- Urine output measurement
- Daily weights
- Fluid balance calculation
- Glucose (if using D5W)

##### Daily Assessment

- Comprehensive metabolic panel
- Magnesium, phosphorus
- Urine osmolality
- Clinical response evaluation

## 💧 Hypotonic Fluid Therapy: Comprehensive Treatment Protocol

### 🎯 Hypotonic Fluid Selection & Administration

#### 📊 Fluid Selection by Clinical Scenario

##### 💧 Hypovolemic Hypernatremia

**Step 1:** Restore hemodynamics

- 0.9% Normal Saline initially
- Goal: Stabilize BP, improve perfusion
- Rate: Based on hemodynamic status

**Step 2:** Switch to hypotonic

- 0.45% saline (77 mEq Na/L)
- When hemodynamically stable
- Lactated Ringer's if acidemic

##### ⚖️ Euvolemic Hypernatremia

**First Choice:** D5W (Free Water)

- 5% Dextrose in Water (0 mEq Na)
- Provides pure free water
- Monitor glucose closely
- Switch to D2.5W if hyperglycemic

**Alternative:** 0.45% saline

- If glucose intolerance
- Slower correction rate
- Monitor for volume overload

##### 💪 Hypervolemic Hypernatremia

**Step 1:** Remove excess sodium

- Furosemide 20-40 mg IV
- Monitor electrolytes closely
- Avoid volume depletion

**Step 2:** Replace with hypotonic

- D5W or 0.45% saline
- Replace urine losses mL for mL
- Daily weights mandatory

#### ⚡ Hypotonic Fluid Characteristics

##### D5W (5% Dextrose)

- Sodium: 0 mEq/L
- Osmolality: 252 mOsm/kg
- Free water: 100%
- Best for euvolemic cases

##### 0.45% Saline

- Sodium: 77 mEq/L
- Osmolality: 154 mOsm/kg
- Free water: ~45%
- Good for hypovolemic cases

##### 0.25% Saline

- Sodium: 34 mEq/L
- Osmolality: 68 mOsm/kg
- Free water: ~75%
- Very hypotonic option

## 💊 Treatment Protocol: Safe Correction Strategies

### 🎯 SAFE CORRECTION PROTOCOL

1 **CALCULATE WATER DEFICIT:** Use corrected formula for age and sex\
• Men: TBW = 0.6 × weight(kg) • Women: TBW = 0.5 × weight(kg) • Elderly: TBW = 0.45 × weight(kg) 2 **DETERMINE CORRECTION RATE:** Maximum 0.5 mEq/L per hour (12 mEq/L per 24h)\
• Chronic/unknown duration: conventional plans often limit the fall to about 10-12 mmol/L/day and below 0.5 mmol/L/h. Adult evidence is uncertain; reassess the measured response and avoid prolonged inadequate correction. Acute sodium loading needs a separate specialist plan. 3 **CHOOSE HYPOTONIC FLUID:** Based on volume status and hemodynamics\
• D5W for euvolemic • 0.45% saline for hypovolemic (after initial NS) • Diuretics + hypotonic for hypervolemic 4 **CALCULATE INFUSION RATE:** Account for ongoing losses\
• Add insensible losses (10-15 mL/kg/day) • Add urine losses • Adjust for fever (increase by 12% per °C \>37°C) 5 **MONITOR CLOSELY:** Serial sodium levels and neurologic status\
• Na+ every 4-6 hours initially • Neurologic checks every 2-4 hours • Adjust rate based on response

#### 🧮 Fluid Rate Calculation Examples

##### Example 1: Euvolemic

**Patient:** 70kg man, Na+ 160 mEq/L

**Water deficit:** 42L × \[(160/140)-1\] = 6L

**Target rate:** 0.5 mEq/L/h = 30 hours minimum

**Fluid choice:** D5W at 200 mL/h + maintenance

##### Example 2: Hypovolemic

**Patient:** 60kg woman, Na+ 155 mEq/L, hypotensive

**Step 1:** 0.9% NS 500-1000 mL for hemodynamics

**Step 2:** Switch to 0.45% saline at 150 mL/h

**Goal:** Na+ decrease by 12 mEq/L over 24h

## 🧮 Interactive Hypernatremia Calculator

### Comprehensive Treatment Calculator

Current Na+ (mEq/L): 155 Patient Weight (kg): 70 Age (years): 65 Gender: Volume Status: Chronicity: Can Access Water: Urine Osmolality: Calculating comprehensive treatment plan...

## ⚠️ Special Considerations & Monitoring

### 🧠 Neurological Complications

- **Cerebral Edema:** Risk with rapid correction
- **Seizures:** Can occur during correction
- **Chronic Adaptation:** Brain generates organic osmolytes
- **Pediatric Risk:** Children more susceptible
- **Monitoring:** Neurologic exam every 2-4 hours

### 💊 Medication Adjustments

- **Lithium:** Consider amiloride if continuing
- **Diuretics:** Hold thiazides and loops initially
- **ACE-I/ARB:** May need temporary discontinuation
- **Demeclocycline:** Stop if causing NDI
- **DDAVP Dosing:** Start low, titrate carefully

### 📊 Monitoring Parameters

- **Sodium:** Every 4-6 hours initially, then q8-12h
- **Urine Output:** Hourly initially, match losses
- **Glucose:** Every 4 hours if using D5W
- **Daily Weights:** Assess volume status changes
- **Neuro Checks:** Mental status, reflexes, symptoms

### 🎯 Key Learning Points

#### 🔍 Diagnostic Priorities

- Most common: lack of free water access
- Urine osmolality is KEY diagnostic test
- Water deprivation test for DI diagnosis
- Distinguish central vs nephrogenic DI

#### 💧 Treatment Essentials

- Correct slowly: ≤0.5 mEq/L per hour
- Choose hypotonic fluid by volume status
- D5W for euvolemic, 0.45% saline for hypovolemic
- Address underlying cause

#### ⚠️ Safety Considerations

- Avoid rapid correction (cerebral edema)
- Monitor neurologic status closely
- Lithium-induced NDI needs amiloride
- Ensure adequate free water access

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Hypernatremia](https://urinenephrology.org/mastery/electrolytes-advanced/hypernatremia.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/sodium/hypernatremia.html) · Markdown synchronized October 3, 2026.